Development

CytoReason has announced an expanded collaboration deal with Pfizer to deliver AI for drug discovery and development.

Novo Nordisk and Microsoft are collaborating to accelerate drug discovery and development using big data and artificial intelligence.

Ensysce Biosciences and Quotient Sciences are partnering to develop and test Ensysce’s novel opioid designed to prevent abuse and overdose.

Research into oncolytic viruses potentiated by stem cells shows promise for treating cancer.

Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.

Using an orthogonal approach to lipid nanoparticle analysis can increase the odds of project success.

The growth of the biopharmaceuticals market is feeding back into economies and, in part, is driving the boom in life sciences and biotech ecosystems.

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.

While a variety of innovations have already impacted the drug delivery landscape, improving sustainability and having the ability to make smaller volumes of drug products still require work.

The projected growth in the biosimilars market will require increased bulk mAb manufacturing.

Scaling up chromatography resins requires a thorough understanding of their intended use.

Forecyte Bio and Cytiva will team up to accelerate the development and manufacturing of cell and gene therapies.

Scientists have developed a mouse model that could be a promising model system for research into factors affecting mammalian embryonic development and disease.

ProBioGen will collobarate with NextPoint Therapeutics to develop and manufacture its lead antibody candidate.

Merck, known as MSD outside of the United States and Canada, will collaborate with Cerevance to identify novel targets for Alzheimer’s disease.

The clinical trial research environment has evolved because of specific solutions designed to overcome uncertainty.

Preclinical testing is better able to evaluate complex drug candidates thanks to innovations in animal model approaches.

Amgen’s acquisition of Chemocentryx includes the autoimmune disease drug Tavneos (avacopan).

Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.

Bio-Rad has expanded its range of recombinant monoclonal anti-idiotypic antibodies.

The new facility in Albany, Ore., will support biopharmaceutical development and lyophilization services.

Experts divulge where the industry is outsourcing most frequently, when companies should outsource more, and when performing tasks in-house might be best.

The growth in demand of viral-vector-based gene therapies drives continuous efforts to improve viral vector manufacturing.

Successful scale-up and BLA filings for products manufactured by microbial biomanufacturing require strategic planning.

FDA and the USPTO hope to promote competition by challenging strategies designed to block timely approval of generics and biosimilars.